{"id":66478,"date":"2026-05-27T20:56:12","date_gmt":"2026-05-27T12:56:12","guid":{"rendered":"https:\/\/flcube.com\/?p=66478"},"modified":"2026-05-27T20:56:14","modified_gmt":"2026-05-27T12:56:14","slug":"astellas-pharma-unveils-csp2026-strategic-plan-targeting-pipeline-driven-growth-and-strategic-brand-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66478","title":{"rendered":"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Astellas Pharma Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4503:TYO\">TYO: 4503<\/a>) has unveiled its <strong>Corporate Strategic Plan 2026 (CSP2026)<\/strong>, a comprehensive five-year growth strategy designed to transition the company from mature product dependency to pipeline-driven revenue generation while maximizing returns from high-margin strategic brands.<\/p>\n\n\n\n<h2 id=\"h-strategic-financial-targets\" class=\"wp-block-heading\">Strategic Financial Targets<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>FY2027 Target<\/th><th>FY2030 Target<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase III\/Pivotal Studies Initiated<\/strong><\/td><td>&gt;5 studies<\/td><td>&gt;10 studies<\/td><\/tr><tr><td><strong>Cumulative Core Operating Profit (pre-R&amp;D)<\/strong><\/td><td>Not specified<\/td><td>&gt;JPY 4.3 trillion (USD 27 billion)<\/td><\/tr><tr><td><strong>Strategic Brands Revenue Growth<\/strong><\/td><td>Interim milestone<\/td><td><strong>2x<\/strong> vs. FY2025 baseline<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-brands-portfolio\" class=\"wp-block-heading\">Strategic Brands Portfolio<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Astellas aims to maximize revenue through five high-margin strategic brands that will serve as the foundation for sustainable funding and capital generation:<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Brand<\/th><th>Therapeutic Area<\/th><th>Growth Catalysts<\/th><\/tr><\/thead><tbody><tr><td><strong>PADCEV<\/strong> (enfortumab vedotin)<\/td><td>Oncology (urothelial cancer)<\/td><td>New indication expansions<\/td><\/tr><tr><td><strong>IZERVAY<\/strong> (avacincaptad pegol)<\/td><td>Ophthalmology (geographic atrophy)<\/td><td>Market penetration acceleration<\/td><\/tr><tr><td><strong>VYLOY<\/strong> (elacestrant)<\/td><td>Oncology (breast cancer)<\/td><td>New indication expansions<\/td><\/tr><tr><td><strong>VEOZAH<\/strong> (fezolinetant)<\/td><td>Women&#8217;s health (vasomotor symptoms)<\/td><td>Geographic expansion<\/td><\/tr><tr><td><strong>XOSPATA<\/strong> (gilteritinib)<\/td><td>On the evening of Sunday (AML)<\/td><td>Lifecycle management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-transition-timeline\" class=\"wp-block-heading\">Strategic Transition Timeline<\/h2>\n\n\n\n<h3 id=\"h-current-phase-fy2025-fy2028\" class=\"wp-block-heading\">Current Phase (FY2025-FY2028)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Core Revenue Driver:<\/strong> Xtandi (enzalutamide) remains significant but declining<\/li>\n\n\n\n<li><strong>Strategic Focus:<\/strong> Build strategic brands portfolio while advancing pipeline<\/li>\n\n\n\n<li><strong>Investment Priority:<\/strong> Clinical development acceleration and regulatory preparation<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-inflection-point-fy2029\" class=\"wp-block-heading\">Inflection Point (FY2029)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Transition:<\/strong> Pipeline products become primary revenue driver<\/li>\n\n\n\n<li><strong>Xtandi Impact:<\/strong> Mature product contribution continues gradual decline<\/li>\n\n\n\n<li><strong>Strategic Brands:<\/strong> Achieve substantial market penetration and revenue scale<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-target-state-fy2030\" class=\"wp-block-heading\">Target State (FY2030)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pipeline Maturity:<\/strong> Multiple late-stage assets contributing to revenue<\/li>\n\n\n\n<li><strong>Strategic Brands:<\/strong> 2x revenue growth vs. FY2025 baseline achieved<\/li>\n\n\n\n<li><strong>Financial Performance:<\/strong> JPY 4.3 trillion cumulative Core OP (pre-R&amp;D) realized<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-growth-strategy-components\" class=\"wp-block-heading\">Growth Strategy Components<\/h2>\n\n\n\n<h3 id=\"h-pipeline-investment\" class=\"wp-block-heading\">Pipeline Investment<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Clinical Development:<\/strong> Accelerated initiation of pivotal studies across therapeutic areas<\/li>\n\n\n\n<li><strong>Capital Allocation:<\/strong> Strategic brands generate funding for pipeline advancement<\/li>\n\n\n\n<li><strong>Risk Management:<\/strong> Diversified portfolio reduces dependency on single assets<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-strategic-brands-maximization\" class=\"wp-block-heading\">Strategic Brands Maximization<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication Expansion:<\/strong> PADCEV and VYLOY targeted for new therapeutic applications<\/li>\n\n\n\n<li><strong>Geographic Growth:<\/strong> New launches in emerging and established markets<\/li>\n\n\n\n<li><strong>Lifecycle Management:<\/strong> Optimized pricing and market access strategies<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-financial-sustainability\" class=\"wp-block-heading\">Financial Sustainability<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>High-Margin Focus:<\/strong> Strategic brands provide superior profitability vs. mature products<\/li>\n\n\n\n<li><strong>R&amp;D Funding Model:<\/strong> Self-sustaining cycle where brand profits fund pipeline development<\/li>\n\n\n\n<li><strong>Capital Efficiency:<\/strong> Targeted investment in highest-probability-of-success programs<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-context-amp-competitive-positioning\" class=\"wp-block-heading\">Market Context &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Industry Challenge:<\/strong> Navigating patent cliffs and generic competition in traditional pharmaceutical model<\/li>\n\n\n\n<li><strong>Astellas Advantage:<\/strong> Early transition to innovative therapies with premium pricing potential<\/li>\n\n\n\n<li><strong>Oncology Leadership:<\/strong> Strong position in targeted cancer therapies with multiple approved assets<\/li>\n\n\n\n<li><strong>Diversification Strategy:<\/strong> Balanced portfolio across oncology, ophthalmology, and women&#8217;s health reduces therapeutic concentration risk<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding Astellas Pharma&#8217;s strategic plan, financial targets, clinical development timelines, and market expectations. Actual results may differ due to risks including regulatory approvals, competitive dynamics, clinical trial outcomes, and market access challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[353,1177],"class_list":["post-66478","post","type-post","status-publish","format-standard","hentry","category-company","tag-astellas-pharma","tag-tyo-4503"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive five-year growth strategy designed to transition the company from mature product dependency to pipeline-driven revenue generation while maximizing returns from high-margin strategic brands.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66478\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion\" \/>\n<meta property=\"og:description\" content=\"Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive five-year growth strategy designed to transition the company from mature product dependency to pipeline-driven revenue generation while maximizing returns from high-margin strategic brands.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66478\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-27T12:56:12+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-27T12:56:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66478#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66478\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion\",\"datePublished\":\"2026-05-27T12:56:12+00:00\",\"dateModified\":\"2026-05-27T12:56:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66478\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Astellas Pharma\",\"TYO: 4503\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66478#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66478\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66478\",\"name\":\"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-05-27T12:56:12+00:00\",\"dateModified\":\"2026-05-27T12:56:14+00:00\",\"description\":\"Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive five-year growth strategy designed to transition the company from mature product dependency to pipeline-driven revenue generation while maximizing returns from high-margin strategic brands.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66478#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66478\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66478#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion - Insight, China&#039;s Pharmaceutical Industry","description":"Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive five-year growth strategy designed to transition the company from mature product dependency to pipeline-driven revenue generation while maximizing returns from high-margin strategic brands.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66478","og_locale":"en_US","og_type":"article","og_title":"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion","og_description":"Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive five-year growth strategy designed to transition the company from mature product dependency to pipeline-driven revenue generation while maximizing returns from high-margin strategic brands.","og_url":"https:\/\/flcube.com\/?p=66478","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-05-27T12:56:12+00:00","article_modified_time":"2026-05-27T12:56:14+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66478#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66478"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion","datePublished":"2026-05-27T12:56:12+00:00","dateModified":"2026-05-27T12:56:14+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66478"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Astellas Pharma","TYO: 4503"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66478#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66478","url":"https:\/\/flcube.com\/?p=66478","name":"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-05-27T12:56:12+00:00","dateModified":"2026-05-27T12:56:14+00:00","description":"Astellas Pharma Inc. (TYO: 4503) has unveiled its Corporate Strategic Plan 2026 (CSP2026), a comprehensive five-year growth strategy designed to transition the company from mature product dependency to pipeline-driven revenue generation while maximizing returns from high-margin strategic brands.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66478#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66478"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66478#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Astellas Pharma Unveils CSP2026 Strategic Plan Targeting Pipeline-Driven Growth and Strategic Brand Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66478"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66478\/revisions"}],"predecessor-version":[{"id":66479,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66478\/revisions\/66479"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}